mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

This agreement marks a significant milestone for both mAbxience and Biosidus, as it represents a strategic advance in their respective areas of expertise. In addition, mAbxience strengthens its position in the CDMO sector, demonstrating its ability to collaborate in the development and manufacture of complex, high-value treatments. For Biosidus, this agreement means a significant milestone in its path to increase its impact in the global pharmaceutical industry, being the first biosimilar molecule for the treatment of a rare disease developed in Latin America and emerging markets, reinforcing its commitment to innovation and access to high quality treatments at affordable prices hand in hand with a solid industrial partner such as mAbxience.

This agreement marks a significant milestone for both mAbxience and Biosidus, as it represents a strategic advance in their respective areas of expertise. In addition, mAbxience strengthens its position in the CDMO sector, demonstrating its ability to collaborate in the development and manufacture of complex, high-value treatments. For Biosidus, this agreement means a significant milestone in its path to increase its impact in the global pharmaceutical industry, being the first biosimilar molecule for the treatment of a rare disease developed in Latin America and emerging markets, reinforcing its commitment to innovation and access to high quality treatments at affordable prices hand in hand with a solid industrial partner such as mAbxience.

The agreement reinforces the vision of both companies to be leaders in the biopharmaceutical industry, combining the technical expertise and production capacity of mAbxience with the innovation and patient focus of Biosidus. This joint effort is expected to have a significant impact on the lives of patients affected by Fabry disease, providing access to essential treatments in Argentina and, subsequently, in other countries around the world.

 

View original content:https://www.prnewswire.co.uk/news-releases/mabxience-and-biosidus-sign-cdmo-agreement-for-the-manufacture-of-agalsidase-beta-for-the-treatment-of-fabry-disease-302051912.html